|
Session 93
Poster Abstracts
Treatment Interruptions and Simplification
Wednesday, 1 - 4 pm
Poster Hall |
513
 |
Risk Factors for Loss of Virological Suppression at 48 Weeks in Patients Receiving Lopinavir/Ritonavir Monotherapy in 2 Clinical Trials Comparing LPV/r Monotherapy vs Triple Therapy with LPV/r (OK and OK04 Trials)
Federico Pulido*1, J Arribas2, J González-Garcia2, J López-Aldeguer3, P Domingo4, V Estrada5, R Rubio1, P Arazo6, J Santamaría7, M Norton8, and OK/OK04 Study Groups
1Hosp Doce de Octubre, Madrid, Spain; 2Hosp La Paz, Madrid, Spain; 3Hosp La Fe, Valencia, Spain; 4Hosp Sant Creu i Sant Pau, Barcelona, Spain; 5Hosp San Carlos, Madrid, Spain; 6Hosp Miguel Servet, Zaragoza, Spain; 7Hosp Basurto, Bilbao, Spain; and 8Abbott Labs, Abbott Park, IL, US |
514
|
Predictors of Loss of Virologic Response in Subjects Who Deintensified to Lopinavir/Ritonavir Monotherapy after Achieving Plasma HIV-1 RNA <50 Copies/mL on LPV/r plus Zidovudine/Lamivudine
R Campo*1, B da Silva2, L Cotte3, J Gathe4, B Gazzard5, C Hicks6, M Dehaan2, K Wikstrom2, M King2, and G Hanna2
1Univ of Miami, Miller Sch of Med, FL, US; 2Abbott Labs, Abbott Park, IL, US; 3Hosp Hotel Dieu, Lyon, France; 4Therapeutic Concepts, Houston, TX, US; 5Chelsea and Westminster Hosp, London, UK; and 6Duke Univ, Durham, NC, US |
515
|
Residual Viremia, but Not HIV DNA Load, Increases in Subjects Undergoing Repeated Treatment Interruptions: A Substudy of the ISS PART Clinical Trial
Lucia Palmisano*, M Giuliano, R Bucciardini, M Andreotti, V Fragola, M Pirillo, L Weimer, M Mancini, R Amici, and S Vella
Inst Superiore di Sanita, Rome, Italy |
516
|
144-Week Clinical and Immunological Outcome of HIV-1-infected Subjects Receiving Lamivudine Monotherapy or Treatment Interruption
Antonella Castagna*, A Danise, L Galli, S Tiberi, N Gianotti, C Vinci, G Fusetti, E Seminari, A soria, and A Lazzarin
San Raffaele Sci Inst, Milan, Italy |
517
|
Predictive Factors of Thrombocytopenia in Patients Randomized to Intermittent or Continuous ART in the ANRS 106 Window Trial
Philippe Tangre*1, I Charreau1, M Lafaurie2, B Marchou3, C Katlama4, P Morlat5, A Polaert1, D Vittecoq6, J P Aboulker1, J M Molina2, and ANRS 106 Study Group
1INSERM SC10, Villejuif, France; 2Hosp St Louis, Paris, France; 3Hosp Purpan, Toulouse, France; 4Hosp Pitie Salpetriere, Paris, France; 5Hosp St Andre, Bordeaux, France; and 6Hosp Paul Brousse, Villejuif, France |
|
